Aduro gets $200m as Novartis steps up immuno-oncology
This article was originally published in Scrip
Aduro Biotech has secured a $200m upfront payment from Novartis as the latter steps up its activity in immunotherapy for cancer. The deal brings Novartis an early-stage immuno-oncology platform targeting the Stimulator of Interferon Genes (STING) pathway, adding to its ongoing programs using chimeric antigen receptor T-cell (CART) technology and checkpoint inhibitors.
You may also be interested in...
Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot
Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Most of the deal's value is in milestone fees, but at $300m up front Bristol is giving IFM's Series A investors a 10X return for drug candidates that can inflame non-responsive tumors.
Immuno-Oncology Data Drive Deal Dollars Higher
Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.